Filing Flows › China Pharma Holdings (CPHI) › Q2 2026
China Pharma Holdings (CPHI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
China Pharma Holdings (CPHI) reported revenue of $948K for the second quarter 2026 (Q2 2026), -8% from a year earlier and -4% from the quarter before. Operating margin was -151.0%, net loss $1.5M (153.8% of revenue).
China Pharma Holdings, Q2 2026: revenue $948K (-8% year over year), operating margin -151.0%, net loss $1.5M, operating cash flow −$33K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $948K | -4% | -8% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.5M | — | — |
| Operating cash flow | −$33K | — | -111% |
What changed
Revenue was $948K in Q2 2026, down 8% year over year and down 4% from the previous quarter.
Gross margin was 8.8%. Operating costs exceeded revenue by $1.4M, an operating margin of -151.0%. The fastest-growing cost line was General & admin (+212%). The quarter ended with a net loss of $1.5M, wider than the previous quarter's $1.1M loss.
Operating cash flow was −$33K. Non-cash charges added back $1.1M of depreciation and amortization. Working capital and other items added $323K.
Questions
What was China Pharma Holdings' revenue in the second quarter 2026?
China Pharma Holdings (CPHI) reported revenue of $948K for the second quarter 2026 (Q2 2026), -8% from a year earlier and -4% from the quarter before.
Was China Pharma Holdings profitable in the second quarter 2026?
Operating loss was $1.4M (-151.0% of revenue) and net loss $1.5M.